Compare Ecolab Inc. (ECL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Novo Nordisk A/S — how do they compare? Ecolab Inc. trades at $273.3 (market cap $76.06B), while Novo Nordisk A/S trades at $50.84 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Ecolab Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| ECL | NVO | |
|---|---|---|
Market Cap | $76.06B | $222.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $71.70 |
52-Week Low | $245.73 | $35.29 |
Enterprise Value | $84.81B | $241.20B |
Dividend Yield | 1.08% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $269.75, down 0.77% on the day, with a bearish technical signal. The stock shows strong fundamentals with 2025 revenue of $16.08B and net income of $2.08B, though recent quarterly EPS results have been mixed. The company recently completed the $4.75B CoolIT acquisition to strengthen its AI cooling portfolio, positioning high-tech as a growth engine. Analyst consensus remains strongly bullish with a $327.43 price target, representing 21% upside potential from current levels.
The outlook is positive given strong analyst support and strategic acquisitions, but risks include execution of the CoolIT integration, rising cost pressures, and mixed quarterly earnings performance. The stock's premium valuation (P/E 36.57) requires sustained earnings growth to justify current levels, making upcoming Q2 2026 results on July 28 critical for near-term direction.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
